CD33 Monoclonal Antibody

domain:Contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.,function:Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).,online information:Siglec-3,PTM:Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6.,similarity:Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.,similarity:Contains 1 Ig-like C2-type (immunoglobulin-like) domain.,similarity:Contains 1 Ig-like V-type (immunoglobulin-like) domain.,subunit:Interacts with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation.,tissue specificity:Monocytic/myeloid lineage cells.,

Introducing the CD33 Monoclonal Antibody, a cutting-edge product designed to revolutionize the field of immunotherapy. This meticulously crafted antibody is specifically engineered to target CD33, a cell surface antigen predominantly expressed on myeloid cells.

With its exceptional specificity and high affinity, the CD33 Monoclonal Antibody offers unparalleled precision in selectively binding to CD33-expressing cells. This attribute makes it an invaluable tool for researchers and clinicians alike, enabling them to effectively identify and isolate myeloid cells for further investigation or therapeutic interventions.

The CD33 Monoclonal Antibody boasts an impressive range of applications, including but not limited to flow cytometry, immunohistochemistry, and immunofluorescence. Its versatility allows for comprehensive analysis of CD33 expression patterns in various biological samples, facilitating a deeper understanding of myeloid cell biology and pathology.

Furthermore, this antibody exhibits exceptional stability and reproducibility, ensuring consistent and reliable results across experiments. Its robust performance, combined with its ease of use, makes it an indispensable asset in any laboratory or clinical setting.

In summary, the CD33 Monoclonal Antibody represents a breakthrough in immunotherapy, offering researchers and clinicians an invaluable tool to advance their understanding and treatment of myeloid cell-related disorders. With its exceptional specificity, versatility, and reliability, this antibody is poised to revolutionize the field and pave the way for novel therapeutic strategies.